Dancann Pharma (DANCAN) Q2 2025 earnings summary

Executive summary

• Q2 2025 saw continued pressure on price and volume, especially for BedrocanⓇ and Bediol, impacting performance; strategic initiatives are underway but expected to show results in 2026.

• Q3 is anticipated to benefit from new product launches (Bedrobinol® and Bedrolite®), broadening the portfolio and strengthening the commercial base.

• The divestment of the Biotech Pharm1 (BP1) production facility is in its final stage, aiming to sharpen strategic focus and redeploy resources for long-term growth.

Financial highlights

• Net sales for Q2 2025 were DKK 1,182 thousand, down from DKK 3,856 thousand in Q2 2024.

• EBITDA for Q2 2025 was DKK -2,236 thousand, compared to DKK 228 thousand in Q2 2024.

• Operating profit (EBIT) for Q2 2025 was DKK -2,735 thousand, versus DKK -274 thousand in Q2 2024.

• Net loss after tax for Q2 2025 was DKK -2,769 thousand, compared to a profit of DKK 447 thousand in Q2 2024.

• Equity at period end was DKK 8,773 thousand, up from DKK 6,589 thousand a year earlier.

Outlook and guidance

• Strategic measures are expected to support profitable growth, but material impact is not anticipated until 2026.

• Q3 2025 is expected to show improved sales, with initial contributions from new product launches.